YD Bio (YDES) director receives $60,000 RSU grant and 2,081 shares
Rhea-AI Filing Summary
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity involving restricted share units (RSUs) that settled into ordinary shares. On March 31, 2026, he received 2,081 RSUs for no cash cost, each representing a right to one ordinary share. The same day, these RSUs were exercised and converted into 2,081 ordinary shares at a conversion price of $0.00 per share, leaving him with 2,081 ordinary shares from this grant and no remaining RSUs from this tranche. The award is part of a broader $60,000 RSU grant under YD Bio’s equity incentive plan, scheduled to vest in four equal quarterly installments based on the stock’s seven‑day volume‑weighted average price before each vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,081 shares
Net Buy
3 txns
Insider
Lu Shao-Ta
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Restricted Share Units | 2,081 | $0.00 | $0.00 |
| Exercise | Restricted Share Units | 2,081 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 2,081 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Share Units — 0 shares (Direct);
Ordinary Shares — 2,081 shares (Direct)
Footnotes (3)
- F1. Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share, par value $0.0001 per share ("Ordinary Share"), of YD Bio Limited.
- F2. The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000 on March 31, 2026 (the "Granted RSUs"). The Granted RSUs vest in four equal quarterly installments beginning on March 31, 2026, with the number of RSUs subject to vesting to be determined on the applicable vesting date by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares ending on the trading day immediately prior to such vesting.
- F3. The Reporting Person became entitled to a fixed number of RSUs on March 31, 2026 (the "Vesting Date").
Key Figures
RSUs granted and vested: 2,081 RSUs
Ordinary shares received: 2,081 shares
Total RSU grant value: $60,000
+1 more
4 metrics
RSUs granted and vested
2,081 RSUs
Vested and converted on March 31, 2026
Ordinary shares received
2,081 shares
Shares issued upon RSU exercise at $0.00 per share
Total RSU grant value
$60,000
Aggregate target grant date fair value of RSUs
Quarterly vesting value
$15,000 per installment
Four equal quarterly installments beginning March 31, 2026
Key Terms
Restricted Share Units, Equity Incentive Plan, volume-weighted average price
3 terms
Equity Incentive Plan financial
"The RSUs were granted pursuant to the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
volume-weighted average price financial
"by dividing $15,000 by the seven (7) trading-day volume-weighted average price of the Company's Ordinary Shares"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did YD Bio (YDES) director Lu Shao-Ta report in this Form 4?
He reported equity compensation activity, not a market trade. On March 31, 2026, 2,081 restricted share units vested and were exercised into 2,081 ordinary shares at $0.00 per share as part of YD Bio’s equity incentive plan.
What is the value of the RSU award reported for YD Bio (YDES) director Lu Shao-Ta?
The RSUs were granted with an aggregate target grant date fair value of $60,000. This value is split into four equal quarterly installments of $15,000 each, with the exact number of RSUs per vesting date determined using the company’s seven‑day volume‑weighted average share price.